Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma - combined performance of multiple markers by Brand, M. van den et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/153070
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Immunohistochemical differentiation between 
follicular lymphoma and nodal marginal zone 
lymphoma – combined performance of multiple
markers
Although many lymphomas can be reliably classified
according to the World Health Organization
Classification of 20081, the differentiation between nodal
marginal zone lymphoma (NMZL) and follicular lym-
phoma (FL) is problematic in some cases. In fact, NMZL
is often diagnosed by exclusion, resulting in heterogene-
ity in the diagnostic category of NMZL. New markers for
NMZL have been described, but they have not yet been
tested in combination.2,3 In this study, we compared mul-
tiple immunohistochemical markers for their use in dis-
tinguishing NMZL from FL. From the results obtained,
we constructed an algorithm that combines these mark-
ers to help distinguish between FL and NMZL. Notably,
this algorithm also contains a category of “B-cell lym-
phoma, unclassifiable”, thus underlining the difficulty
that remains in distinguishing NMZL from FL. 
For the initial test series, we selected 47 patients with
FL with a chromosomal rearrangement of BCL2, and 44
patients with a diagnosis of NMZL or probable NMZL,
from the archive of the Department of Pathology at the
Radboud university medical center (Nijmegen, the
Netherlands). For all NMZLs, BCL2 translocations were
excluded using fluorescent in-situ hybridization with
split-signal probes. Patient characteristics are described in
Online Supplementary Table S1. For a diagnosis of NMZL,
the following diagnostic criteria were used: 1) effaced
architecture of the lymph node, due to a small B-cell pro-
liferation with a follicular, marginal zone, or diffuse
growth pattern, 2) either centrocytoid or more round
cells with intermingled centroblasts, 3) a mature B-cell
immunophenotype with expression of BCL2, 4) in cases
with a follicular/ nodular growth pattern, signs of follicu-
lar colonization (presence of BCL2 negative cells and high
Ki67 staining), 5) not fitting a diagnosis of chronic lym-
phocytic leukemia/small lymphocytic lymphoma, mantle
cell lymphoma, or lymphoplasmacytic lymphoma.
Expression of germinal center markers was not consid-
ered an exclusion criterion for a diagnosis of NMZL in
this study.
As expected, immunohistochemistry showed signifi-
cant differences between NMZL and FL (Table 1).
Overall, FLs were positive for germinal center markers
(CD10, BCL6, LMO2, HGAL) and negative for MNDA
and IRTA1 (Online Supplementary Figure S1). NMZLs
mostly showed an opposite pattern with positivity for
MNDA in approximately two thirds of cases, IRTA1
staining in approximately one fifth of cases and usually
no staining with germinal center markers. However, all
germinal center markers were positive in a subset of
NMZLs, and similarly, FLs with expression of MNDA
were also identified (Online Supplementary Figure S2). 
Based on the immunohistochemistry results, a combi-
nation of markers were used to design an algorithm that
helped to distinguish NMZL from FL (Figure 1). This algo-
rithm was built empirically, allowing inclusion of a cate-
gory of “B-cell lymphoma, unclassifiable” to prevent con-
tamination of the NMZL category. As expected, this algo-
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Table 1. Immunohistochemistry results.
Number of positive cases n (%) Sensitivity and Specificity (%)
Initial series Validation series Initial series Validation series
NMZL FL NMZL FL Se Sp Se Sp
(n=44) (n=47) (n=13) (n=21)
BCL6 5 (11) 44 (94) 3 (23) 21 (100) 94 89 100 77
CD10 8 (18) 42 (89) 2 (15) 21 (100) 89 82 100 85
HGAL 11 (25) 44 (94) 1(8) 17(81) 94 75 81 92
LMO2 12 (27) 41 (87) 1 (8) 14 (67) 87 73 67 92
4/4 GCM1 2 (5) 36 (77) 0 (0) 11 (52) 77 95 52 100
MNDA 31 (70) 6 (13) 9 (69) 4 (19) 70 87 69 81
IRTA1 6 (14) 0 (0) 6 (46) 0 (0) 14 100 46 100
14/4 GCM: 4 out of 4 germinal center markers positive; FL: follicular lymphoma; NMZL: nodal marginal zone lymphoma; Se: sensitivity; Sp: specificity. 
Figure 1. Immunohistochemical algorithm for separation of nodal
marginal zone lymphoma (NMZL) from follicular lymphoma (FL).
The algorithm starts at the top with a lymphoma that is considered
to be either FL or NMZL. If all four germinal center markers (BCL6,
CD10, LMO2, HGAL) are positive, a diagnosis of FL is made. If not,
IRTA1 expression is determined. If IRTA1 is positive, a diagnosis of
NMZL is made. If IRTA1 is negative, MNDA and germinal center
markers are used to divide the remaining cases into three cate-
gories: NMZL for MNDA positive cases with positivity for none or
only one germinal center marker, FL for MNDA negative cases with
expression of 2 or 3 germinal center markers and low-grade B-cell
lymphoma, unclassifiable for cases that do not fit into either of
these two categories.© 
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rithm classified most lymphomas according to their orig-
inal diagnosis (Table 2). However, in the initial test series,
one case of FL was classified as NMZL, and 6 cases of
NMZL were classified as FL by the algorithm; a signifi-
cant proportion of cases (13%) were considered “B-cell
lymphoma, unclassifiable” by the algorithm. Most (75%)
of these unclassifiable cases had an original diagnosis of
NMZL.
To validate the algorithm, a second validation group of
21 FLs and 13 NMZLs, collected from the archive of the
Department of Pathology at the Hospital del Mar
(Barcelona, Spain) was stained for the same markers as
the initial group. Overall, staining results were compara-
ble to those in the test group, with a high sensitivity of
BCL6 for FL and a high specificity of IRTA1 for NMZL
(Table 1); CD10 expression had a higher sensitivity in
comparison to the test group, but a lower specificity.
LMO2 and HGAL were less sensitive but more specific. 
In this validation group, the algorithm gave a concor-
dant classification as either NMZL or FL in 85% of cases
(Table 2). No follicular lymphoma was misclassified as
NMZL, and only one NMZL was misclassified as FL. Four
cases (12%) were considered unclassifiable, three of
which had an original diagnosis of FL and one with an
original diagnosis of NMZL.
The algorithm was designed based on a comparison of
NMZLs with FLs with a translocation involving BCL2.
However, because a BCL2 translocation can be demon-
strated relatively easily, the actual problem we are faced
with in daily practice is the separation of NMZL from FL
without a BCL2 translocation. FLs with and without a
BCL2 translocation might be different from each other, as
has been suggested by one gene expression study4, and
also by a recent comparative genomic hybridization
study.5 In the latter study, genetic aberrations in FLs with-
out a BCL2 translocation bore more resemblance to those
in NMZL than those in FLs with a BCL2 translocation. To
address this problem, we tested a small series of 6 FLs
without a BCL2 translocation, which were all classified as
FL by the algorithm. This supports the idea that this algo-
rithm also applies to FLs without a BCL2 translocation,
but confirmation of this theory will require the study of a
larger series.
Thus far, the majority of the markers in the algorithm
has only been described in single studies. Kanellis and
colleagues reported expression of MNDA in 75% of
NMZLs versus 5% of FLs.2 In our series, a less pro-
nounced, but similar difference was observed, with
MNDA expression in NMZL and FL in 70% and 15%,
respectively. In accordance with Falini and colleagues6,
IRTA1 also discriminated between NMZL and FL in our
series. However, in the study carried out by Falini et
al.,73% of NMZLs expressed IRTA1, compared to only
21% in our study. This difference could be caused by a
difference in interpretation. In our case, faint IRTA1
expression was quite frequently observed in NMZLs, but
also in some FLs. As the reproducibility of the scores
assigned to these cases proved to be very poor amongst
different observers, a case was only considered positive if
30% or more of the cells showed moderate or strong
expression of IRTA1. This aforementioned approach pro-
duced a strong improvement in the diagnostic value of
IRTA1 in our series, and explains the small proportion of
NMZLs positive for IRTA1. 
Expression of the germinal center markers HGAL and
LMO2 in lymphomas has been described by Natkunam et
al., whose work showed expression in the majority of FLs
and only very rare expression in NMZL.7-10 For both
markers, they detected only a single case of NMZL that
was positive.7,8 In our series, we observed more frequent
expression of both LMO2 and HGAL in NMZL. We
believe this could be caused by differences in inclusion
criteria between our study and previous studies. In the
study effected by Salama et al., which contains the largest
majority of NMZLs previously studied for LMO2 and
HGAL, cases were excluded from the NMZL group if
they expressed germinal center markers9, which explains
why expression of germinal center markers was not
detected in NMZLs in their study. A recent study by
Dyhdalo and colleagues reported LMO2 staining in 2 out
of 25 NMZLs, of which one case also expressed BCL6.11
In our study, expression of germinal center markers was
not considered an exclusion criterion. We made this
choice because, in our experience, typical cases of NMZL
do occasionally express germinal center markers and
expression of CD10 and BCL6 in NMZL has been previ-
ously reported.12-14
The FLs that were used to build the algorithm were all
required to have a BCL2 break, which, together with
morphology, ensured that the diagnosis of FL was cor-
rect. Thus, misclassification of FL with a BCL2 break as
NMZL has been excluded. Unfortunately, no markers for
NMZL can compare with the BCL2 translocation for FL.
Therefore, the NMZL group can still be expected to be
more heterogeneous than the FL group, with some cases
representing FL or other lymphomas rather than NMZL.
Indeed, when looking at the initial and validation series
together, ‘NMZLs’ were quite frequently considered FL
(in 12%) or unclassifiable (in 18%) by the algorithm. This
illustrates the difficulty that remains in the definition and
diagnosis of NMZL; the lack of both an accurate defini-
tion and of positive diagnostic markers for NMZL result
in a heterogeneous diagnostic category.
The ultimate question is: what is the gold standard?
For this study we have used the combination of morphol-
ogy and phenotyping for follicular colonization as defin-
ing criteria for NMZL. The addition of extensive
immunohistochemistry, including new markers, might
help to create a better gold standard for NMZL. At pres-
ent, however, it is very difficult to compare different
strategies to diagnose NMZL, due to the fact that as of
yet no perfect positive marker for NMZL is available.
Hopefully, elucidation of the pathogenesis of NMZL will
provide us with better positive markers for NMZL. The
results from this study could assist in achieving this goal;
the addition of extensive immunohistochemistry to con-
ventional criteria for NMZL will help to establish smaller,
but potentially more homogeneous study groups, facili-
tating studies into the pathogenesis of NMZL.
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Table 2. Algorithm results.
Diagnosis Initial series Validation series
n (%) n (%)
FL NMZL FL NMZL
FL 43 (91) 6 (14) 18 (86) 1 (8)
B-cell 3 (6) 9 (20) 3 (14) 1 (8)
lymphoma, unclassifiable
NMZL 1 (2) 29 (66) 0 (0) 11 (85)
FL: follicular lymphoma; NMZL: nodal marginal zone lymphoma.
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